From: Hepatitis C-related cryoglobulinemic neuropathy: potential role of oxcarbazepine for pain control
Patients (total 67) | Features |
---|---|
Age (years) | 50.4 ± 2.7 |
Sex ratio (M/F) | 31/36 |
Apparent duration of disease (years) | 4.1 ± 1.3 |
Albumin level (g/L) | 39.7 ± 8.5 |
ALT (IU/L) | 131.4 ± 16.7 |
Prothrombin time (%) | 84.1 ± 12.2 |
Rheumatoid factors (n of pts. and %) | 41/67 (61%) |
Mean Cryoglobulinemia(g/L) | 0.27 ± 0.8 |
Cryoglobulinemia type | |
 CGS TYPE II (n of pts. and %) | 42/67 (64%) |
 CGS TYPE III (n of pts. and %) | 25/67 (36%) |
 ANTI HCV Antibodies (n of pts. and %) | 67/67 (100%) |
 ANTI HBV Antibodies (n of pts. and %) | 35/67 (52%) |
 Anti HBC | 30 (86%) |
 HBsAg | 5 (14.2) |
 Anti HBS | 30 (86%) |
 HBeAG | 0 |
 AntiHBe | 0 |
 HCV RNA sequences in sera (n of pts. and %) | 49/67 (73%) |